MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma

Low-grade gliomas (LGG) represent the most common type of central nervous system (CNS) neoplasm in children.(1-3) Importantly, pediatric-type LGGs, affecting children and young adults, are molecularly distinct from adult-type LGGs. While the latter typically harbor IDH1 or IDH2 mutations, pediatric-type LGGs invariably involve activation of the mitogen-activated protein kinase (MAPK) cascade.(4,5) While adult-type LGG often progress into higher grade gliomas over time, pediatric-type LGGs are associated with excellent overall survival of >95%.(4 )Nonetheless, they are at risk for progression many years after diagnosis and patients may suffer functional morbidity.